SuperworthPrecigen PGEN
- Market cap
- $2.2B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a quarter missing
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- −5.2%
Precigen's trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | $1.3M | $856K | n/a | n/a | $23.3M+1634% | $55M+6323% | |
| Cost of revenue | n/a | n/a | n/a | n/a | n/a | n/a | $1.1M | $1.1M | n/a | n/a | $2.6M+133% | $2.8M+157% |
| Gross profit | n/a | n/a | n/a | n/a | n/a | n/a | $241K | −$236K | n/a | n/a | $20.7M+8486% | $52.2M |
| R&D | n/a | n/a | n/a | n/a | n/a | n/a | $10.5M | $11.5M | n/a | n/a | $5.6M−46% | $7.3M−37% |
| SG&A | n/a | n/a | n/a | n/a | n/a | n/a | $12.4M | $16.1M | n/a | n/a | $21M+70% | $22.2M+38% |
| n/a | n/a | n/a | n/a | n/a | n/a | −$22.6M | −$31.8M | n/a | n/a | −$6M−74% | $22.6M | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | $1K | $0 | n/a | n/a | $2.9M+290700% | $3M |
| Pre-tax income | −$19.8M+157% | −$33.4M+51% | −$23.8M+4% | −$60.5M+197% | −$24M+21% | −$19.8M−41% | −$54.2M+128% | −$26.6M−56% | n/a | n/a | −$7.9M−85% | $20.1M |
| −$6K−88% | −$332K | −$29K−47% | −$1.7M+2499% | $12K | −$87K−74% | $0 | $3K | $0 | n/a | $0 | $0 | |
| Net income | −$19.8M | −$33.1M+49% | −$23.7M+4% | −$58.8M+189% | −$24M+21% | −$19.7M−40% | −$54.2M+128% | −$26.6M−55% | −$146.3M+510% | −$23.5M+19% | −$7.9M−85% | $20.1M |
| −$0.08 | −$0.13+18% | −$0.10+0% | −$0.23+188% | −$0.09+13% | −$0.07−46% | −$0.18+80% | −$0.09−61% | −$1.06+1078% | −$0.07+0% | −$0.02−89% | $0.05 | |
| 248.5M+24% | 248.9M+24% | 249.2M+9% | 252.4M+2% | 275.9M+11% | 293M+18% | 293.9M+18% | 296.4M+18% | 307.2M+11% | 353.8M+21% | 354.3M+21% | 413.7M+40% |
Gross profit: 29 periods, Q3 FY13 to Q2 FY26: not printed by the filing, worked out from its own lines.
R&D: Q1 FY12: 6 months less the 3 months printed beside them.
SG&A: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them.
Operating income: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them. 18 periods, Q1 FY19 to Q2 FY23: not printed by the filing, worked out from its own lines.
Interest expense: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them.
Net income: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them.
EPS, diluted: 11 periods, Q1 FY12 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY12: share-days: the 6-month average less the second quarter's. 13 periods, Q4 FY12 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY14: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Precigen's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| PGENPrecigen | $2.2B | n/m | 13.2× | n/m | n/m | n/m | |
| PBHPrestige Consumer Healthcare | $2.3B | 13.4× | 15.3× | 2.0× | −1% | 15.6% | |
| HRMYHarmony Biosciences | $2.1B | 11.7× | 13.8× | 2.2× | +24% | 18.9% | |
| NRIXNurix Therapeutics | $2.8B | 11.0× | 10.8× | 3.9× | n/m | 42.0% | |
| ANIPANI Pharmaceuticals | $1.7B | 15.4× | 60.6× | 1.7× | +31% | 11.1% | |
| PAHCPhibro Animal Health | $1.6B | 15.9× | 21.5× | 1.0× | +17% | 6.6% | |
| ANABAnaptysbio | $1.5B | 10.7× | 100.0× | n/m | n/m | n/m | |
| PCRXPacira BioSciences | $1.5B | 104× | 65.6× | 1.9× | +6% | 2.0% | |
| OGNOrganon | $3.6B | 17.9× | 5.9× | 0.6× | −2% | 3.4% | |
| LQDALiquidia | $3.8B | 30.7× | 53.6× | 8.5× | n/m | 30.7% | |
| ARQTArcutis Biotherapeutics | $3.9B | 142× | 115× | 8.5× | +76% | 6.1% | |
| Peer median | $2.2B | 15.7× | 37.5× | 2.0× | +17% | 11.1% |
More on Precigen
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .